In this episode of “Blood Cancer Talks,” Uma Borate, MBBS, of the Ohio State University, joins the hosts to discuss clonal cytopenias of unknown significance (CCUS).
Dr. Borate outlines the diagnosis process, as well as monitoring and management strategies for CCUS.
The episode highlights CCUS risk stratification approaches, scoring systems, and recent research on predicting the likelihood of CCUS transformation to a myeloid neoplasm. Dr. Borate and the hosts also discuss studies on the germline predisposition to clonal hematopoiesis, and how cancer treatments impact clonal hematopoiesis.
Additionally, Dr. Borate and the hosts cover the IMPACT study, which evaluated canakinumab for the prevention of progression to cancer in patients with CCUS, as well as a study of ivosidenib in patients with CCUS and mutations in IDH1.
This podcast originally appeared on Blood Cancer Talks.